Skip to main content
NCBI home page
World Journal of Gastroenterology logoLink to World Journal of Gastroenterology
. 2003 Apr 15;9(4):745–750. doi: 10.3748/wjg.v9.i4.745

Is laparoscopy an advantage in the diagnosis of cirrhosis in chronic hepatitis C virus infection?

Perdita Wietzke-Braun 1, Felix Braun 1, Peter Schott 1, Giuliano Ramadori 1
PMCID: PMC4611442  PMID: 12679924

Abstract

AIM: To evaluate the potential of laparoscopy in the diagnosis of cirrhosis and outcome of interferon treatment in HCV-infected patients.

METHODS: In this retrospective study, diagnostic laparoscopy with laparoscopic liver biopsy was performed in 72 consecutive patients with chronic HCV infection. The presence or absence of cirrhosis was analyzed macroscopically by laparoscopy and microscopically by liver biopsy specimens. Clinical and laboratory data and outcome of interferon-alfa treatment were compared between cirrhotic and noncirrhotic patients.

RESULTS: Laparoscopically, cirrhosis was seen in 29.2% (21/72) and non-cirrhosis in 70.8% (51/72) of patients. Cirrhotic patients were significantly older with a significant longer duration of HCV infection than noncirrhotic patients. Laboratory parameters (AST, y-GT, y-globulin fraction) were measured significantly higher as well as significantly lower (prothrombin index, platelet count) in cirrhotic patients than in non-cirrhotic patients. Histologically, cirrhosis was confirmed in 11.1% (8/72) and non cirrhosis in 88.9% (64/72). Patients with macroscopically confirmed cirrhosis (n = 21) showed histologically cirrhosis in 38.1% (8/21) and histologically non-cirrhosis in 61.9% (13/21). In contrast, patients with macroscopically non-cirrhosis (n = 51) showed histologically non cirrhosis in all cases (51/51). Thirty-nine of 72 patients were treated with interferon-alfa, resulting in 35.9% (14/39) patients with sustained response and 64.1% (25/39) with non response. Non-responders showed significantly more macroscopically cirrhosis than sustained responders. In contrast, there were no significant histological differences between non-responders and sustained responders.

CONCLUSION: Diagnostic laparoscopy is more accurate than liver biopsy in recognizing cirrhosis in patients with chronic HCV infection. Liver biopsy is the best way to assess inflammatory grade and fibrotic stage. The invasive marker for staging, prognosis and management, and treatment outcome of chronic HCV-infected patients need further research and clinical trials. Laparoscopy should be performed for recognition of cirrhosis if this parameter is found to be of prognostic and therapeutic relevance in patients with chronic HCV infection.

INTRODUCTION

Hepatitis C virus (HCV) infection is the leading cause of chronic liver disease. Up to 85% of HCV-infected patients develop chronic liver disease without elimination of the virus[1-3]. Chronic HCV infected patients develop cirrhosis in 7% and 20% after 20 and 40 years of infection[4], while symptoms and alarming biochemical markers appear late[5,6]. Patients with cirrhosis secondary to chronic HCV infection also have an increased risks for development of hepatocellular carcinoma (HCC), estimated to be between 1%-4% per year[7].

The diagnostic spectrum for chronic hepatitis C includes biochemical parameters, antibodies against HCV, qualitative and quantitative HCV RNA with genotyping, abdominal ultrasound and liver histology. Random core biopsy analysis can reveal information about the inflammatory grade and fibrotic stage of chronic HCV infection[8]. Diagnosis of compensated liver cirrhosis can be made with a high accuracy neither by percutaneous liver biopsy nor by ultrasound[9]. In comparison with percutaneous liver biopsy, laparoscopy allows macroscopic inspection of both liver lobes that might variate during progression of liver disease[10]. Percutaneous liver biopsy only allows the interpretation of a small biopsy. It has been reported that histological analysis fail with error ranges above 25% in the diagnosis of cirrhosis in chronic liver disease[11,12], especially during the early phase of cirrhosis (Child A) and macronodular cirrhosis[13]. In a retrospective study, Poniachik et al[14] compared the presence of cirrhosis in 434 patients by liver biopsy and laparoscopy. Cirrhosis was seen laparoscopically in 169 patients and was confirmed in 115 patients histologically. In contrast, only 2 of 265 histologically confirmed cirrhotic livers were macroscopically without cirrhosis. Ultrasound guided liver biopsy can result in a false negative histology due to the puncture of a regenerative nodule[15]. Cardi et al[16] showed superiority of laparoscopy over ultrasonography in diagnosis of widespread liver diseases. Oberti et al[17] reported that only prothrombin index and serum hyalorunate were sensitive parameters for screening cirrhosis. Early cirrhosis may often be missed due to clinical inappearance especially in patients with chronic HCV infection and accurate noninvasive markers of disease activity and fibrosis are not available[18]. The absence of early cirrhosis in chronic HCV infected patients might be a potential field for diagnostic laparoscopy that is not performed routinely and patients with early cirrhosis can be enrolled in the screening programs for HCC, too.

In the treatment of chronic HCV infection has proved beneficial interferon-alfa in the last two decades[19-23]. Old age, high level of viraemia, HCV genotype II (1b), long duration of disease, high levels of hepatic iron store, especially the advanced liver damage represented by dimension of fibrosis were considered to be negative predictive factors in the outcome of interferon treatment[22,24-34]. Two studies focused exclusively on interferon treatment in patients with HCV related cirrhosis[35,36]. After introduction of pegylated interferon given only once a week, HCV-infected patients with cirrhosis or bridging fibrosis were treated in a clinical trial[37]. These data implicated that HCV infected patients with liver cirrhosis need different therapeutic schedules with longer duration and higher dose of interferon.

Since cirrhosis is a negative predictor for antiviral therapy in chronic HCV-infected patients and liver histology might underestimate the frequency of cirrhosis, the aim of this retrospective study was to evaluate the potential of laparoscopy in the diagnosis of cirrhosis and outcome of interferon treatment in this particular group of patients.

MATERIALS AND METHODS

Patients

Laparoscopy and laparoscopic liver biopsy were performed in 72 chronic HCV-infected patients. Diagnosis of chronic HCV infection was based on elevated liver enzymes for at least 6 months, detection of anti-HCV antibodies in ELISA (2nd generation) and HCV RNA by RT/PCR. Patients with active viral coinfections (HBV, HIV, CMV, EBV), evidence for autoimmune hepatitis with positive serologic constellation of specific autoantibodies (ANA, AMA, anti-SLA, SMA, anti-LKM), alcohol and/or i.v. drug abusers and patients with signs of liver cirrhosis and/or hepatic decompensation (e.g. ascites, gastrointestinal bleeding, etc.) were excluded. Each patient was asked to sign a written informing consent for diagnostic laparoscopy and liver biospy.

Biochemical and serological analysis

Serum levels of ALT, AST, γ-GT, AP and CHE, as well as concentrations of serum bilirubin, prothrombin index, γ-globuline fraction and platelet count were measured by established routine methods before laparoscopy, during and after interferon treatment. Anti-HCV antibodies were analyzed using an ELISA (2nd generation, Ortho Diagnostic Systems, Raritan, NJ, USA) according to the instructions of the manufacturer.

Detection of HCV RNA and determination of HCV genotypes

According to Okamoto et al and Simmonds et al[38,39] determination of serum HCV RNA by a nested RT/PCR technique and determination of genotypes by a restriction enzyme analysis were carried out as described previously[40].

Laparoscopy

Abdominal ultrasound, electrocardiogram and, in patients older than 60 years, a chest X-ray were performed before laparoscopy. The evening before laparoscopy, each patient received 75 mg promethazin orally. Two hours before examination, 50 mg promethazin and 30 minutes before exploration 50 mg pethidin and 0.5 mg atropine were injected intramascularly. If necessary, patients received sedativa or analgetics during the laparoscopic intervention. During laparoscopy, each patient was given continuously an isotonic electrolyte solution intravenously. Patients were monitored by pulsoxymetry. After local anesthesia, the pneumoperitoneum was installed by puncturing at Monros’point with the Verres needle followed by insufflation of 2-3 L nitrous oxide. After insertion of the laparoscope in a trocar with a safety shield at Kalks’point, macroscopic exploration of liver, spleen and peritoneum followed. Liver biopsies were taken generally from an area on the anterior surface of the left lobe of the liver or of macroscopic suspect areas using a Menghini needle, at least 2 cm from the liver edge, containing at least five portal areas. Macroscopic diagnosis of cirrhosis was made based on the following criteria: (1) diffuse nodules on the liver surface, or (2) shallow nodules (i.e., nodules usually of large diameter, slightly protruding from the liver surface) if the liver was hard on palpation and rigid on lifting with a blunt probe and if clearcut features of portal hypertension were observed[41,42].

Histopathological evaluation

Formalin-fixed and paraffin-embedded liver biopsies were stained with hematoxylin-eosin, trichrome and by applying the Prussian blue reaction as described previously[43]. One pathologist examined samples unblindedly. A modified “Histology Activity Index” (HAI) on the basis of reported staging scores served to assess the stage of fibrosis[44-46]. Absent portal fibrosis was staged as fibrosis score I (HAIb = 0, no fibrosis), mild to moderate fibrosis as stage II (HAIb = 1, fibrotic portal expansion), marked fibrosis as stage III (HAIb = 3, bridging fibrosis) and complete fibrosis as cirrhosis (HAIb = 4).

Interferon treatment

Patients received recombinant interferon-alfa 2a (Roferon A, Hoffmann-La Roche, Basel, Switzerland) for initial treatment of chronic HCV infection. In our retrospective study, a dose of 6 MU three times a week was administered for 12 months according to Chemello et al[47]. Patients were classified as sustained responders if serum transaminases normalized (biochemical response) and serum HCV RNA became undetectable (virological response) during the treatment and at 6 months after the end of treatment (follow-up). During the follow-up, the re-emergence of both parameters after the end of treatment was defined as relapse. Patients with no improvement of biochemical or virological parameters within the first 3 months of treatment were classified as non-responders and treatment was stopped. For statistical analysis patients with relapse and non-response were classified as non-responders and compared with sustained responders. Patients who finished their course of treatment and 6 months of follow-up after the end of treatment were analysed.

Statistical analysis

Significant levels of differences between values were analyzed using the Chi-square test, Mann-Whitney test and student’s t-test as indicated.

RESULTS

Mean (M ± SD) age of the 72 patients (49% female, 51% male) with chronic HCV infection was 46.8 ± 12.1 years with a range of 27-72 years. Route and date of HCV infection were identified in 44 patients. The duration of HCV infection was 15.4 ± 9.7 years and route of viral transmission was blood transfusion in 23%, intravenous drug abuse in 18% and anti-D prophylaxis in 3%.

Laparoscopy found no severe complications. Liver biopsy caused mild bleeding in 6 (8%) patients which was controlled during laparoscopy by local compression. None of the patients required blood transfusion. One patient developed a mesenteric emphysema after insufflation of nitrous oxide.

Cirrhosis was found by laparoscopy in 21/72 (29.2%) patients and by histology in 8/72 (11.1%) patients. According to HAI, patients with macroscopic cirrhosis by laparoscopy (n = 21) showed histologically fibrosis stage I in 14.3% (3/21), fibrosis stage II in 19% (4/21), fibrosis stage III in 28.6% (6/21) and cirrhosis in 38,1% (8/21) (Table 1). Therefore 13/21 (61.9%) macroscopic cirrhosis was not identified histologically. No cirrhosis was detected by laparoscopy in 51/72 (70.8%) patients. According to HAI, patients without macroscopic cirrhosis (n = 51) showed histologically fibrosis stage I in 58.8% (30/51), fibrosis stage II in 31.4% (16/51), fibrosis stage III in 9.8% (5/51) and cirrhosis in 0 (0/51).

Table 1.

Outcome of macroscopic laparoscopic exploration and histological analysis in 72 patients with chronic HCV infection

Histology (fibrosis stage score) Laparoscopy
Patients without signs of cirrhosis (n = 51) Patients with signs of cirrhosis (n = 21)
Fibrosis I 30 3
Fibrosis II 16 4
Fibrosis III 5 6
Cirrhosis 0 8
Open in a new tab

Absent portal fibrosis was judged as fibrosis score I (HAIb = 0, no fibrosis), mild to moderate fibrosis as stage II (HAIb = 1, fibros portal expansion), marked fibrosis as stage III (HAIb = 3, bridg-ing fibrosis), and complete fibrosis as cirrhosis (HAIb = 4).

For statistical analysis, patients were divided into two groups. Group A represented patients with macroscopic cirrhosis (n = 21) and group B patients without macroscopic cirrhosis (n = 51) diagnosed by laparoscopic criteria. The mean (M ± SD) age of patients in group A was 56.4 ± 9.4 years, being significantly higher than in group B aged 41.7 ± 11.2 years (P < 0.02). There were 10 men and 11 women in group A and 27 men and 24 women in group B (n.s.). Mean (M ± SD) duration of chronic HCV infection in 44 patients of group A was 23.2 ± 8.3 years, being significantly longer than in patients without macroscopic cirrhosis (group B) aged 10.4 ± 5.7 years (P < 0.02) (Table 2). In blood chemistry, patients of group A had significantly higher AST, γ-GT and γ-globulin fraction in serum electrophoresis as well as significant lower prothrombin index and platelet count than patients of group B. No significant differences were found for ALT, AP, bilirubin and cholinesterasis in both groups (Table 3). According to the Child-Pugh-Turcotte classification, 18 of the 21 patients with macroscopic cirrhosis were classified as Child A, 3 Child B and none Child C. In comparison of histological cirrhosis (8/21) and histologic non cirrhosis (13/21) of group A with macroscopic cirrhosis (n = 21), significant differences were only found in AST and y-GT (Table 4). Differences were not significant in prothrombin index, y-globuline fraction and platelet count between cirrhosis (8/21) and histologic non-cirrhosis (13/21) of group A with macroscopic cirrhosis (n = 21) (Table 4).

Table 2.

Demographic and clinical data of patients with and without laparoscopically diagnosed cirrhosis

Laparoscopy
 P
Patients with signs of Cirrhosis (n = 21) Patients without signs of Cirrhosis (n = 51)
Age (years) 56.36 ± 9.42 41.7 ± 11.2 < 0.02a
Duration of disease 23.2 ± 8.3 10.4 ± 5.68 < 0.02a
(years) (n = 44)
Sex ratio (m/f) 10/11 27/24 ns
Open in a new tab
a

Student’s t-test (unpaired); ns = not significant, years were showed as mean ± standard deviation. Duration of disease could be evaluated in 44 cases by patients’ history.

Table 3.

Laboratory data of patients with and without laparoscopic macroscopic evidence of cirrhosis

Laboratory data Laparoscopy
 P
Patients with evidence of cirrhosis (n = 21) Patients without evidence of cirrhosis (n = 51)
AST (U/l) 59.7 ± 54.2 29.3 ± 19.6 < 0.02
ALT (U/l) 82.5 ± 70.3 72.6 ± 47.2 ns
γ-GT (U/l) 72.6 ± 78.4 34.1 ± 38.2 < 0.02
AP (U/l) 129.8 ± 48.9 137.5 ± 49.6 ns
Bilirubin (mg/dl) 1.1 ± 0.93 1.86 ± 6.23 ns
CHE (U/l) 5114 ± 1331 5910 ± 1001 ns
Prothrombin index (%) 93.8 ± 12.6 102.2 ± 6.3 < 0.02
γ-globuline fraction (%) 19.9 ± 6.5 13.7 ± 2.9 < 0.02
Platelet count (cell/µl) 172940 ± 65068 253230 ± 57096 < 0.02
Open in a new tab

All data were showed as mean ± standard deviation. Statisti-cal analysis was performed by applying Mann-Whitney test. ns = not significant.

Table 4.

Comparing laboratory data of patients with macro-scopic laparoscopic signs of cirrhosis

Laboratory data Histological analysis
 P
No cirrhosis (n = 13) Cirrhosis (n = 8)
AST (U/l) 35.9 ± 24.9 87.7 ± 67.8 < 0.02
ALT (U/l) 64.9 ± 72.2 97.0 ± 66.34 ns
γ-GT (U/l) 51.64 ± 39.78 103.0 ± 104.6 < 0.02
AP (U/l) 126.3 ± 54.6 144.6 ± 39.6 ns
Bilirubin (mg/dl) 0.36 ± 0.5 1.4 ± 3.438 ns
CHE (U/l) 5129 ± 1861 4685 ± 1773 ns
Prothrombin index (%) 95.8 ± 10.6 90.7 ± 14.3 ns
γ-globuline fraction (%) 16.3 ± 3.2 19.6 ± 10.6 ns
Platelet count (cells/µl) 180700 ± 56240 167000 ± 77110 ns
Open in a new tab

All data were showed as mean ± standard deviation, statisti-cal analysis were performed by Mann-Whitney test. ns = not significant.

Thirty-nine patients were treated with interferon-alfa 2a and followed up for 6 months after the end of treatment. HCV genotyping was performed in all 39 patients before start of therapy. HCV genotype II (1b) was the predominat genotype. The HCV genotypes of the 39 patients were 23 II (1b), 5 I (1a), 3 IV (2b), 5 V (3a) and 3 I (1a) combined with II (1b). Patients with macroscopic cirrhosis showed no significant difference of genotype distribution as compared with patients without cirrhosis. Interferon treatment resulted in 14/39 (35.9%) sustained responders and 25/39 (64.1%) non-responders including 2 relapsers. According to HCV genotype distribution, a significant higher rate of genotype II (1b) was observed in non-responders than sustained responders (P < 0.02). Non-responders had a higher rate of macroscopic cirrhosis than sustained responders (P < 0.02) (Table 5).

Table 5.

Comparisons in pretreatment parameters between patients with sustained response and patients with non-re-sponse to interferon treatment (n = 39)

Sustained-responders Non-responders P
Number (%) 14 (35.9%) 25 (64.1%)
Age (years) 50.6 ± 13.9 47.2 ± 10.6 ns
Genotype 1b (%) 5 (35.7%) 18 (72%) < 0.02a
Fibrosis staging score (%)
I 7 (50.0%) 9 (36.0%)
II 3 (21.4%) 8 (32.0%)
III 3 (21.4%) 3 (12.0%)
Cirrhosis 1 (7.0%) 5 (20.0%) ns
Laparoscopic evidence 2 (14.2%) 9 (36.0%) < 0.02a
of cirrhosis (%)
Open in a new tab

Data of age were showed as mean ± standard deviation;

a

Chi-square test, ns = not significant.

DISCUSSION

Diagnostic laparoscopy is recommended in the diagnosis of peritoneal diseases, evaluation of ascites of unknown origin, staging of abdominal cancer and chronic and focal liver disease[48]. Laparoscopy is commonly not performed for the diagnosis of cirrhosis in patients with chronic HCV. The availability of percutaneous liver biospy guided by ultrasound, CT- or MRI-scan offers selected biopsy of an suspicious area in the liver. The rate of laparoscopic liver biopsies in gastroenterology declined and also the number of training programs for this procedure[49]. However, all imaging procedures do not allow a direct viewing of the liver. The direct visual inspection of the liver and the abdomen is the privilege of laparoscopy.

In this study, more chronic HCV infected patients had been diagnosed of cirrhosis macroscopically by laparoscopic inspection of the liver than histologically by using the Menghini needle for laparoscopic liver biopsy. All patients with histological cirrhosis also had cirrhosis macroscopically, but 13/21 patients with macroscopic cirrhosis had no cirrhosis histologically. This discrepancy implicates an underestimation of cirrhosis in chronic HCV-infected patients, if diagnosis of cirrhosis is based only on liver biopsy using the Menghini needle. Poniachik et al[14] investigated the role of laparoscopy and laparoscopic liver biopsy in the diagnosis of cirrhosis in 434 patients with chronic liver disease including 169 patients with laparoscopic evidence of cirrhosis. The histological sampling error was 32% among patients documented to have cirrhosis by laparoscopy. The selection of a suction or cutting needle for liver biopsy has a major impact at the stage of cirrhosis. The use of a cutting needle like Vim-Silverman or Tru-Cut is reported to give a more representive histology than suction needles like Menghini, Klatskin or Jamshidi, because fibrotic tissue tends to fragment with the use of suction needle[49,50]. In a randomized study on 1192 patients with diffuse liver disease, Colombo et al[51] investigated percutaneous liver biopsies comparing the Tru-Cut and the Menghini needle. For diagnosing cirrhosis accuracy of the Tru-Cut needle is significantly better (89.5%) than the Menghini needle (65.5%). Complication rates were very low with both needles.

Comparing laparoscopy and laparoscopic biopsy for diagnosis of cirrhosis, laparoscopic diagnosis of macroscopic cirrhosis was of higher value than histological diagnosis of microscopic cirrhosis regarding blood chemistry and the response to interferon therapy. The rate of non-response to interferon therapy was 64.1% in our study. Significant parameters for non-response were genotype II (1b) and laparoscopic evidence of cirrhosis, but not histological diagnosis of cirrhosis. Nowadays, new therapeutic regimes have replaced interferon monotherapy. The combination of interferon-alfa with ribavirin improved sustained response rate for chronic HCV-infected patients[52] and for relapsers and non-responders after initially interferon monotherapy[53-55]. Increased efficacy was shown with pegylated interferon as compared with standard interferons in cirrhotic and noncirrhotic patients with chronic hepatitis C[37,56,57] and currently standard therapy is pegylated interferon in combination with ribavirin[8]. In this treatment situation, the role of liver biopsy has increasingly been discussed[58]. If patients with positive predictors of virological response, such as low viral load and infection with genotype 2 or 3, can be treated and have very high chances of response, a biopsy that reveals mild histologic changes may do little to dissuade the clinician and patients from immediate treatment[8]. Liver biopsy may become recommended only in those patients whose pretreatment characteristics predict the lowest success rate[8]. Paired liver biopsy specimens enable staging of inflammation and fibrosis before and after treatment to define histological response in those patients. Compaired with our data, the rate of cirrhosis before treatment will be underestimated without performing laparoscopy in those patients. Both procedures, liver biopsy and laparoscopy, are invasive, but accurate noninvasive markers for staging disease activity, fibrosis and cirrhosis are not available[18]. Our rate of complications related to laparoscopy and laparoscopic liver biopsy was 10% and no severe complication was observed. These data are in accordance with other reports[11,42,59-62]. The rate of severe complications using blind percutaneous liver biopsy is reported to be 0.3%-1.5% and is almost comparable with laparoscopic liver biopsy[41,63-67]. Diagnostic laparoscopy and laparoscopic liver biopsy are a safe and invasive procedure in patients with compensated liver disease. Minilaparoscopy has increasingly emerged as a less invasive diagnostic method in this field[68].

Based on our data, diagnostic laparoscopy is indicated for recognition of early cirrhosis in patients with chronic HCV infection. In fact, as early diagnosis of cirrhosis affects management of chronic HCV infected patients, it should be the key factor in the decision-making process.

Footnotes

Edited by Ma JY and Xu XQ

References

  • 1.Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, Hu PY, Miller JK, Gerber MA, Sampliner RE. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med. 1992;327:1899–1905. doi: 10.1056/NEJM199212313272702. [DOI] [PubMed] [Google Scholar]
  • 2.Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology. 1997;26:15S–20S. doi: 10.1002/hep.510260703. [DOI] [PubMed] [Google Scholar]
  • 3.Ramadori G, Meier V. Hepatitis C virus infection: 10 years after the discovery of the virus. Eur J Gastroenterol Hepatol. 2001;13:465–471. doi: 10.1097/00042737-200105000-00001. [DOI] [PubMed] [Google Scholar]
  • 4.Dore GJ, Freeman AJ, Law M, Kaldor JM. Is severe liver disease a common outcome for people with chronic hepatitis C? J Gastroenterol Hepatol. 2002;17:423–430. doi: 10.1046/j.1440-1746.2002.02730.x. [DOI] [PubMed] [Google Scholar]
  • 5.Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology. 1991;14:969–974. doi: 10.1016/0270-9139(91)90113-a. [DOI] [PubMed] [Google Scholar]
  • 6.Zeuzem S, Roth WK, Herrmann G. [Viral hepatitis C] Z Gastroenterol. 1995;33:117–132. [PubMed] [Google Scholar]
  • 7.Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology. 1997;26:34S–38S. doi: 10.1002/hep.510260706. [DOI] [PubMed] [Google Scholar]
  • 8.Herrine SK. Approach to the patient with chronic hepatitis C virus infection. Ann Intern Med. 2002;136:747–757. doi: 10.7326/0003-4819-136-10-200205210-00010. [DOI] [PubMed] [Google Scholar]
  • 9.Gaiani S, Gramantieri L, Venturoli N, Piscaglia F, Siringo S, D'Errico A, Zironi G, Grigioni W, Bolondi L. What is the crite-rion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy. J Hepatol. 1997;27:979–985. doi: 10.1016/s0168-8278(97)80140-7. [DOI] [PubMed] [Google Scholar]
  • 10.Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, Feng ZZ, Reddy KR, Schiff ER. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002;97:2614–2618. doi: 10.1111/j.1572-0241.2002.06038.x. [DOI] [PubMed] [Google Scholar]
  • 11.Jalan R, Harrison DJ, Dillon JF, Elton RA, Finlayson ND, Hayes PC. Laparoscopy and histology in the diagnosis of chronic liver disease. QJM. 1995;88:559–564. [PubMed] [Google Scholar]
  • 12.Nord HJ. Biopsy diagnosis of cirrhosis: blind percutaneous versus guided direct vision techniques--a review. Gastrointest Endosc. 1982;28:102–104. doi: 10.1016/s0016-5107(82)73015-9. [DOI] [PubMed] [Google Scholar]
  • 13.Vido I, Wildhirt E. [Correlation of the laparoscopic and histological findings in chronic hepatitis and liver cirrhosis] Dtsch Med Wochenschr. 1969;94:1633–1637. doi: 10.1055/s-0028-1110315. [DOI] [PubMed] [Google Scholar]
  • 14.Poniachik J, Bernstein DE, Reddy KR, Jeffers LJ, Coelho-Little ME, Civantos F, Schiff ER. The role of laparoscopy in the diagnosis of cirrhosis. Gastrointest Endosc. 1996;43:568–571. doi: 10.1016/s0016-5107(96)70192-x. [DOI] [PubMed] [Google Scholar]
  • 15.Mössner J. [Laparoscopy in differential internal medicine diagnosis] Z Gastroenterol. 2001;39:1–6. [PubMed] [Google Scholar]
  • 16.Cardi M, Muttillo IA, Amadori L, Petroni R, Mingazzini P, Barillari P, Lisi D, Bolognese A. Superiority of laparoscopy compared to ultrasonography in diagnosis of widespread liver diseases. Dig Dis Sci. 1997;42:546–548. doi: 10.1023/a:1018895009305. [DOI] [PubMed] [Google Scholar]
  • 17.Oberti F, Valsesia E, Pilette C, Rousselet MC, Bedossa P, Aubé C, Gallois Y, Rifflet H, Maïga MY, Penneau-Fontbonne D, et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology. 1997;113:1609–1616. doi: 10.1053/gast.1997.v113.pm9352863. [DOI] [PubMed] [Google Scholar]
  • 18.Saadeh S, Cammell G, Carey WD, Younossi Z, Barnes D, Easley K. The role of liver biopsy in chronic hepatitis C. Hepatology. 2001;33:196–200. doi: 10.1053/jhep.2001.20534. [DOI] [PubMed] [Google Scholar]
  • 19.Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL. Treat-ment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med. 1989;321:1501–1506. doi: 10.1056/NEJM198911303212203. [DOI] [PubMed] [Google Scholar]
  • 20.Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, Banks SM, Hoofnagle JH. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med. 1989;321:1506–1510. doi: 10.1056/NEJM198911303212204. [DOI] [PubMed] [Google Scholar]
  • 21.Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski JP. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology. 1996;24:778–789. doi: 10.1002/hep.510240405. [DOI] [PubMed] [Google Scholar]
  • 22.Hoofnagle JH, di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med. 1997;336:347–356. doi: 10.1056/NEJM199701303360507. [DOI] [PubMed] [Google Scholar]
  • 23.Saracco G, Borghesio E, Mesina P, Solinas A, Spezia C, Macor F, Gallo V, Chiandussi L, Donada C, Donadon V, et al. Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter random-ized trial. J Hepatol. 1997;27:56–62. doi: 10.1016/s0168-8278(97)80280-2. [DOI] [PubMed] [Google Scholar]
  • 24.Mizokami M, Orito E, Gibo Y, Suzuki K, Ohba K, Ohno T, Lau JY. Genotype, serum level of hepatitis C virus RNA and liver histology as predictors of response to interferon-alpha 2a therapy in Japanese patients with chronic hepatitis C. Liver. 1996;16:23–27. doi: 10.1111/j.1600-0676.1996.tb00699.x. [DOI] [PubMed] [Google Scholar]
  • 25.Rumi M, Del Ninno E, Parravicini ML, Romeo R, Soffredini R, Donato MF, Wilber J, Russo A, Colombo M. A prospective, randomized trial comparing lymphoblastoid to recombinant interferon alfa 2a as therapy for chronic hepatitis C. Hepatology. 1996;24:1366–1370. doi: 10.1002/hep.510240609. [DOI] [PubMed] [Google Scholar]
  • 26.Jouët P, Roudot-Thoraval F, Dhumeaux D, Métreau JM. Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Le Groupe Français pour l'Etude du Traitement des Hépatites Chroniques NANB/C. Gastroenterology. 1994;106:686–690. doi: 10.1016/0016-5085(94)90703-x. [DOI] [PubMed] [Google Scholar]
  • 27.Pagliaro L, Craxí A, Cammaá C, Tiné F, Di Marco V, Lo Iacono O, Almasio P. Interferon-alpha for chronic hepatitis C: an analysis of pretreatment clinical predictors of response. Hepatology. 1994;19:820–828. [PubMed] [Google Scholar]
  • 28.Tsubota A, Chayama K, Ikeda K, Yasuji A, Koida I, Saitoh S, Hashimoto M, Iwasaki S, Kobayashi M, Hiromitsu K. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology. 1994;19:1088–1094. [PubMed] [Google Scholar]
  • 29.Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, Degott C, Descombes I, Le Breton V, Milotova V. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology. 1995;22:1050–1056. [PubMed] [Google Scholar]
  • 30.Nousbaum JB, Pol S, Nalpas B, Landais P, Berthelot P, Bréchot C. Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group. Ann Intern Med. 1995;122:161–168. doi: 10.7326/0003-4819-122-3-199502010-00001. [DOI] [PubMed] [Google Scholar]
  • 31.Kanazawa Y, Hayashi N, Mita E, Li T, Hagiwara H, Kasahara A, Fusamoto H, Kamada T. Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients. Hepatology. 1994;20:1121–1130. [PubMed] [Google Scholar]
  • 32.Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Izumi N, Marumo F, Sato C. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest. 1995;96:224–230. doi: 10.1172/JCI118025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Van Thiel DH, Friedlander L, Fagiuoli S, Wright HI, Irish W, Gavaler JS. Response to interferon alpha therapy is influenced by the iron content of the liver. J Hepatol. 1994;20:410–415. doi: 10.1016/s0168-8278(94)80017-0. [DOI] [PubMed] [Google Scholar]
  • 34.Shindo M, Arai K, Okuno T. The clinical value of grading and staging scores for predicting a long-term response and evaluating the efficacy of interferon therapy in chronic hepatitis C. J Hepatol. 1997;26:492–497. doi: 10.1016/s0168-8278(97)80412-6. [DOI] [PubMed] [Google Scholar]
  • 35.Valla DC, Chevallier M, Marcellin P, Payen JL, Trepo C, Fonck M, Bourliere M, Boucher E, Miguet JP, Parlier D, et al. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology. 1999;29:1870–1875. doi: 10.1002/hep.510290616. [DOI] [PubMed] [Google Scholar]
  • 36.Shiratori Y, Yokosuka O, Nakata R, Ihori M, Hirota K, Katamoto T, Unuma T, Okano K, Ikeda Y, Hirano M, et al. Prospective study of interferon therapy for compensated cirrhotic patients with chronic hepatitis C by monitoring serum hepatitis C RNA. Hepatology. 1999;29:1573–1580. doi: 10.1002/hep.510290529. [DOI] [PubMed] [Google Scholar]
  • 37.Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, Reindollar R, Reddy RK, Wright TL, Lin A, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med. 2000;343:1673–1680. doi: 10.1056/NEJM200012073432302. [DOI] [PubMed] [Google Scholar]
  • 38.Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, Tanaka T, Sato K, Tsuda F, Miyakawa Y. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol. 1992;73(Pt 3):673–679. doi: 10.1099/0022-1317-73-3-673. [DOI] [PubMed] [Google Scholar]
  • 39.Simmonds P, McOmish F, Yap PL, Chan SW, Lin CK, Dusheiko G, Saeed AA, Holmes EC. Sequence variability in the 5' non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity. J Gen Virol. 1993;74(Pt 4):661–668. doi: 10.1099/0022-1317-74-4-661. [DOI] [PubMed] [Google Scholar]
  • 40.Polzien F, Schott P, Mihm S, Ramadori G, Hartmann H. Interferon-alpha treatment of hepatitis C virus-associated mixed cryoglobulinemia. J Hepatol. 1997;27:63–71. doi: 10.1016/s0168-8278(97)80281-4. [DOI] [PubMed] [Google Scholar]
  • 41.Pagliaro L, Rinaldi F, Craxì A, Di Piazza S, Filippazzo G, Gatto G, Genova G, Magrin S, Maringhini A, Orsini S, et al. Percutaneous blind biopsy versus laparoscopy with guided biopsy in diagnosis of cirrhosis. A prospective, randomized trial. Dig Dis Sci. 1983;28:39–43. doi: 10.1007/BF01393359. [DOI] [PubMed] [Google Scholar]
  • 42.Henning H, Look D. 1985. Laparoskopie: Atlas und Lehrbuch. Stuttgart Thieme; pp. 32–46. [Google Scholar]
  • 43.Mihm S, Fayyazi A, Hartmann H, Ramadori G. Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype. Hepatology. 1997;25:735–739. doi: 10.1002/hep.510250340. [DOI] [PubMed] [Google Scholar]
  • 44.Desmet VJ. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis [Hepatology 1981; 1: 431-435] J Hepatol. 2003;38:382–386. doi: 10.1016/s0168-8278(03)00005-9. [DOI] [PubMed] [Google Scholar]
  • 45.Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 1994;19:1513–1520. [PubMed] [Google Scholar]
  • 46.Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696–699. doi: 10.1016/0168-8278(95)80226-6. [DOI] [PubMed] [Google Scholar]
  • 47.Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, Belussi F, Frezza M, Noventa F, Pontisso P. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. The TriVeneto Viral Hepatitis Group. Hepatology. 1995;22:700–706. doi: 10.1002/hep.1840220303. [DOI] [PubMed] [Google Scholar]
  • 48.Nord HJ. What is the future of laparoscopy and can we do without it? Z Gastroenterol. 2001;39:41–44. [PubMed] [Google Scholar]
  • 49.Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med. 2001;344:495–500. doi: 10.1056/NEJM200102153440706. [DOI] [PubMed] [Google Scholar]
  • 50.Goldner F. Comparison of the Menghini, Klatskin and Tru-Cut needles in diagnosing cirrhosis. J Clin Gastroenterol. 1979;1:229–231. doi: 10.1097/00004836-197909000-00007. [DOI] [PubMed] [Google Scholar]
  • 51.Colombo M, Del Ninno E, de Franchis R, De Fazio C, Festorazzi S, Ronchi G, Tommasini MA. Ultrasound-assisted percutaneous liver biopsy: superiority of the Tru-Cut over the Menghini needle for diagnosis of cirrhosis. Gastroenterology. 1988;95:487–489. doi: 10.1016/0016-5085(88)90509-4. [DOI] [PubMed] [Google Scholar]
  • 52.McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339:1485–1492. doi: 10.1056/NEJM199811193392101. [DOI] [PubMed] [Google Scholar]
  • 53.Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Craxi A, Ling MH, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339:1493–1499. doi: 10.1056/NEJM199811193392102. [DOI] [PubMed] [Google Scholar]
  • 54.Cheng SJ, Bonis PA, Lau J, Pham NQ, Wong JB. Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials. Hepatology. 2001;33:231–240. doi: 10.1053/jhep.2001.20675. [DOI] [PubMed] [Google Scholar]
  • 55.Wietzkebetaraun P, Meier V, Braun F, Ramadori G. Combination of "low-dose" ribavirin and interferon alfa-2a therapy followed by interferon alfa-2a monotherapy in chronic HCV-infected non-responders and relapsers after interferon alfa-2a monotherapy. World J Gastroenterol. 2001;7:222–227. doi: 10.3748/wjg.v7.i2.222. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000;343:1666–1672. doi: 10.1056/NEJM200012073432301. [DOI] [PubMed] [Google Scholar]
  • 57.Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson G, Reindollar R, Fried MW, Purdum PP, Jensen D, Smith C, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology. 2001;33:433–438. doi: 10.1053/jhep.2001.21747. [DOI] [PubMed] [Google Scholar]
  • 58.Griffiths A, Viiala CH, Olynyk JK. Liver biopsy in the 21st century: where and why? Med J Aust. 2002;176:52–53. doi: 10.5694/j.1326-5377.2002.tb04282.x. [DOI] [PubMed] [Google Scholar]
  • 59.Phillips RS, Reddy KR, Jeffers LJ, Schiff ER. Experience with diagnostic laparoscopy in a hepatology training program. Gastrointest Endosc. 1987;33:417–420. doi: 10.1016/s0016-5107(87)71677-0. [DOI] [PubMed] [Google Scholar]
  • 60.Adamek HE, Maier M, Benz C, Huber T, Schilling D, Riemann JF. [Severe complications in diagnostic laparoscopy. 9 years experience in 747 examinations] Med Klin (Munich) 1996;91:694–697. [PubMed] [Google Scholar]
  • 61.Brühl W. [Incidents and complications in laparoscopy and directed liver puncture. Result of a survey] Dtsch Med Wochenschr. 1966;91:2297–2299. doi: 10.1055/s-0028-1111690. [DOI] [PubMed] [Google Scholar]
  • 62.Leinweber B, Korte M, Kratz F, Gerhardt H, Matthes KJ. [Laparoscopy. Results and experiences] Med Welt. 1975;26:1762–1765. [PubMed] [Google Scholar]
  • 63.Terry R. Risks of needle biopsy of the liver. Br Med J. 1952;1:1102–1105. doi: 10.1136/bmj.1.4768.1102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Sherlock S, Dick R, Van Leeuwen DJ. Liver biopsy today. The Royal Free Hospital experience. J Hepatol. 1985;1:75–85. doi: 10.1016/s0168-8278(85)80070-2. [DOI] [PubMed] [Google Scholar]
  • 65.Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol. 1986;2:165–173. doi: 10.1016/s0168-8278(86)80075-7. [DOI] [PubMed] [Google Scholar]
  • 66.Perrault J, McGill DB, Ott BJ, Taylor WF. Liver biopsy: complications in 1000 inpatients and outpatients. Gastroenterology. 1978;74:103–106. [PubMed] [Google Scholar]
  • 67.Knauer CM. Percutaneous biopsy of the liver as a procedure for outpatients. Gastroenterology. 1978;74:101–102. [PubMed] [Google Scholar]
  • 68.Helmreich-Becker I, Meyer zum Büschenfelde KH, Lohse AW. Safety and feasibility of a new minimally invasive diagnostic laparoscopy technique. Endoscopy. 1998;30:756–762. doi: 10.1055/s-2007-1001417. [DOI] [PubMed] [Google Scholar]

Articles from World Journal of Gastroenterology : WJG are provided here courtesy of Baishideng Publishing Group Inc

RESOURCES